Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Viva Biotech Holdings ( (HK:1873) ) is now available.
Viva Biotech Holdings has scheduled a board meeting for March 30, 2026 to review and approve the group’s audited annual results for the financial year ended December 31, 2025. The board will also decide whether to recommend a final dividend for shareholders, signaling potential returns depending on the company’s performance and capital-allocation priorities.
The meeting will additionally authorize the publication of the 2025 results, providing the market with updated financial and operational information about the group. The announcement confirms the current composition of the board, highlighting a mix of executive, non-executive and independent non-executive directors overseeing the company’s governance and strategic decisions.
The most recent analyst rating on (HK:1873) stock is a Hold with a HK$2.50 price target. To see the full list of analyst forecasts on Viva Biotech Holdings stock, see the HK:1873 Stock Forecast page.
More about Viva Biotech Holdings
Viva Biotech Holdings is a Hong Kong-listed company incorporated in the Cayman Islands and engaged in the biopharmaceutical sector. The group operates through Viva Biotech and its subsidiaries, focusing on biotech-related services and solutions for global pharmaceutical and life sciences clients.
Average Trading Volume: 10,057,620
Technical Sentiment Signal: Buy
Current Market Cap: HK$4.42B
For an in-depth examination of 1873 stock, go to TipRanks’ Overview page.